Resources from the same session
179O - Combination of olaparib, durvalumab and fulvestrant in patients with advanced ER-positive, HER2-negative breast cancer harboring homologous recombination repair (HRR) deficiency or microsatellite instability (MSI): Results of the international phase II DOLAF trial
Presenter: Séverine Guiu
Session: Proffered Paper session 1
Resources:
Abstract
Slides
Webcast
180O - IMpassion132 double-blind randomised phase III trial of chemotherapy (CT) ± atezolizumab (atezo) for early-relapsing unresectable locally advanced or metastatic triple-negative breast cancer (aTNBC)
Presenter: Rebecca Dent
Session: Proffered Paper session 1
Resources:
Abstract
Slides
Webcast
181O - Interim analysis (IA) of the atezolizumab (atezo) + sacituzumab govitecan (SG) arm in patients (pts) with triple-negative breast cancer (TNBC) in MORPHEUS-pan BC: A phase Ib/II study of multiple treatment (tx) combinations in pts with locally advanced/metastatic BC (LA/mBC)
Presenter: Peter Schmid
Session: Proffered Paper session 1
Resources:
Abstract
Slides
Webcast
Q&A and discussion
Session: Proffered Paper session 1
Resources:
Webcast